Synergy Pharmaceuticals (NASDAQ:SGYP) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Tuesday, February 6th.
A number of other equities research analysts have also issued reports on the company. Cantor Fitzgerald reissued a “buy” rating and set a $10.00 price target on shares of Synergy Pharmaceuticals in a research note on Thursday, January 25th. Citigroup downgraded Synergy Pharmaceuticals to a “market perform” rating in a report on Friday, January 5th. Canaccord Genuity set a $13.00 price objective on Synergy Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, November 12th. Oppenheimer reiterated a “market perform” rating and issued a $10.00 price target on shares of Synergy Pharmaceuticals in a report on Friday, January 5th. Finally, HC Wainwright set a $7.00 price target on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 4th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.28.
Shares of Synergy Pharmaceuticals (NASDAQ SGYP) opened at $2.05 on Tuesday. Synergy Pharmaceuticals has a one year low of $1.68 and a one year high of $6.45. The company has a quick ratio of 3.88, a current ratio of 4.26 and a debt-to-equity ratio of -68.13. The stock has a market capitalization of $505.65, a P/E ratio of -1.77 and a beta of 1.13.
COPYRIGHT VIOLATION NOTICE: “Synergy Pharmaceuticals (SGYP) Downgraded by BidaskClub” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2018/02/15/synergy-pharmaceuticals-sgyp-stock-rating-lowered-by-bidaskclub.html.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.